Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia

16. november 2026 opdateret af: Jiangsu Guiqiong Pharmaceutical Co., Ltd.

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia

This is a multicenter, randomized, double-blind, placebo-controlled, dose-finding Phase II clinical study to evaluate the efficacy and safety of SXRN injection in adult patients with cancer-associated anorexia-cachexia. This study comprises a double-blind treatment phase, followed by an open-label treatment phase for eligible participants upon completion of the double-blind phase.

Studieoversigt

Detaljeret beskrivelse

This is a multicenter, randomized, double-blind, placebo-controlled, dose-finding Phase II clinical study designed to evaluate the efficacy and safety of SXRN injection in adult patients with cancer-associated anorexia-cachexia.

Eligible participants are randomly assigned at a 1:1:1 ratio to one of three treatment arms: Arm A (4 mg SXRN injection), Arm B (6 mg SXRN injection), or Arm C (placebo). During the double-blind treatment phase, study drug or placebo is administered via intravenous infusion once daily for 5 consecutive days followed by a 2-day break, for a total of 3 weeks (21 days). Investigators and participants remain blinded to treatment assignment during this phase.

Upon completion of the double-blind phase, participants assessed by the investigator as having no clinical progression or intolerable toxicity will enter the open-label treatment phase and receive a uniform dose of 4 mg SXRN injection. The dosing regimen in the open-label phase is identical to that in the double-blind phase: 5 consecutive days of dosing followed by a 2-day break, with each cycle of 21 days. Participants will continue study treatment until any of the following occurs: disease progression, intolerable toxicity, withdrawal of informed consent, loss to follow-up, death, or other pre-defined treatment discontinuation criteria, whichever comes first.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

96

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Beijing, Kina
        • National Cancer Center/Cancer Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

The participant must meet all the criteria below:

  • 1. Male or female, aged 18~75 at the time of signing the ICF;

  • 2. Histologically or cytologically confirmed advanced malignancy of one of the following: pancreatic cancer; non-small cell lung cancer (NSCLC); colorectal cancer;

  • 3. Disease status and prior treatment history (meet any one of the following):

    1. Pancreatic cancer: Locally advanced (unresectable) or metastatic pancreatic ductal adenocarcinoma, with treatment failure after at least 2 lines of prior systemic anti-tumor therapy (may include gemcitabine, nab-paclitaxel, irinotecan, platinum agents, and fluoropyrimidines);
    2. Non-small cell lung cancer (NSCLC): Stage IIIB/IV NSCLC, with treatment failure after at least 2 lines of prior systemic anti-tumor therapy (must include platinum-based chemotherapy; patients with positive driver gene must have received corresponding targeted therapy);
    3. Colorectal cancer: Metastatic colorectal cancer, with treatment failure after at least 3 lines of prior systemic anti-tumor therapy (must include fluoropyrimidines, oxaliplatin, and irinotecan); patients with MSI-H/dMMR tumors must have received anti-PD-1/PD-L1 therapy followed by treatment failure.
  • 4. Diagnosis of cancer anorexia-cachexia based on the cachexia staging criteria from the 2025 Chinese Guidelines for the Diagnosis and Treatment of Cancer Anorexia-Cachexia Syndrome with consideration of Chinese population characteristics, i.e., meeting the following criteria (either ①② or ①③):

    1. Involuntary weight loss >5% in 6 months; OR weight loss >2% when BMI <18.5 kg/m²; OR weight loss >2% accompanied by muscle mass depletion;
    2. Anorexia (VAS score ≤70, or FAACT-A/CS-12 score ≤37);
    3. CRP>5 mg/L;
  • 5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2;

  • 6. Expected survival time ≥12 weeks;

  • 7. Lab results and organ function tested within 7 days before the initial infusion meet the following criteria:

Complete Blood Count: Absolute Neutrophil Count (ANC) ≥ 1.0×109/L; Platlets (PLT) Count ≥ 75×109/L; Hemoglobins (Hb) ≥ 80 g/L.

Note: Participants with chronic anemia caused by underlying tumor or cachexia may be enrolled if the investigator assesses the condition as stable; anemia resulting from active bleeding is excluded.

Blood Biochemistry: Total bilirubin (TBIL) ≤3.0 × upper limit of normal (ULN); Serum creatinine (SCr) ≤1.5 × ULN or creatinine clearance (CrCl) by Cockroft-Gault formula ≥30 mL/min; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0×ULN; for participants with concurrent liver metastases, AST and ALT ≤5.0×ULN and ALP ≤6.0×ULN;

Blood coagulation function: International Normalized Ratio (INR), Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT) ≤1.5×ULN.

Note: for participants receiving precautious anti-coagulation treatment, the investigator shall determine whether INR and APTT remains in a safe and effective range for treatment.

Echocardiogram: Left Ventricular Ejection Fraction (LVEF) ≥50%;

  • 8. Participants are capable of understanding and voluntarily signing the written informed consent form (ICF); participants must be willing and able to complete study procedures and follow-up assessments.

Exclusion Criteria:

Participants who meet any of the criteria below must be excluded:

  • 1. Reversible causes of reduced dietary intake as determined by the investigator, which may include but are not limited to mechanical obstruction resulting in patients' inability to eat;

  • 2. Patients who have received any appetite-enhancing or weight-loss-improving medications (including marketed prescription drugs and investigational agents under clinical trial) within 28 days before the first study drug administration or 5 half-lives of the drug (whichever is shorter), including but not limited to anamorelin, progestogens such as medroxyprogesterone acetate, cannabinoids, and medical cannabis;

  • 3. Patients who are only able to receive tube feeding and parenteral nutrition and cannot take food orally;

  • 4. Patients with cachexia clearly attributable to other underlying conditions, such as severe chronic obstructive pulmonary disease (COPD), AIDS, etc.;

  • 5. Hormonal therapies judged by the investigator to have effects for improving tumor anorexia-cachexia;

  • 6. Patients who have undergone major surgery or interventional procedures within 4 weeks prior to the first dose, or who are scheduled to receive such procedures during the trial (excluding tumor biopsy, puncture, etc.);

  • 7. Patients with toxicities from previous antitumor therapies that have not yet recovered to ≤ Grade 2 or baseline levels (except for toxicities judged by the investigator as to pose no safety risk, such as alopecia, or asymptomatic hypothyroidism induced by immune checkpoint inhibitors that is stable and only requires thyroid hormone replacement therapy);

  • 8. Clinically uncontrolled serous cavity effusion (pleural effusion, ascites, pericardial effusion): moderate or greater effusion; local therapy (including drainage, peritoneal shunt, cell-free concentrated ascites reinfusion therapy, etc.) within 2 weeks before screening or planned within 2 weeks; significant effusion increase within 2 weeks after local therapy; requirement for long-term indwelling catheter. Participants meeting any condition or deemed by the investigator unsuitable for enrollment will be excluded;

  • 9. Patients with central nervous system metastases requiring intervention;

  • 10. History of other malignancies, except for those who have undergone curative treatment with no recurrence within 5 years, such as carcinoma in situ of the cervix, basal cell carcinoma of the skin, etc.;

  • 11. History of immunodeficiency, including acquired or congenital immunodeficiency diseases, organ transplantation, allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation;

  • 12. (Non-infectious) pulmonary inflammation/interstitial lung disease requiring steroid therapy within 4 weeks prior to the first infusion;

  • 13. Participants with a history of severe cardiovascular and cerebrovascular diseases, including but not limited to:

    1. Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, second- to third-degree atrioventricular block, etc.;
    2. Participants with New York Heart Association (NYHA) Class III-IV cardiac dysfunction;
    3. Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other Grade ≥3 cardiovascular and cerebrovascular events occurring within 6 months prior to the first study drug administration;
  • 14. Hypertension uncontrolled by a stable regimen of antihypertensive medication (systolic blood pressure ≥160 mmHg, and/or diastolic blood pressure ≥100 mmHg);

  • 15. Participants with active chronic hepatitis B (e.g., HBsAg positive or HBcAb positive with HBV DNA above the lower limit of detection), active hepatitis C (e.g., HCV antibody positive with HCV RNA above the lower limit of detection), or human immunodeficiency virus (HIV) infection;

  • 16. Active infection requiring systemic therapy within 2 weeks prior to the first dose;

  • 17. History of active tuberculosis infection within 1 year prior to the first dose;

  • 18. Any other uncontrolled or significant comorbid disease(s), either currently or historically, that by the investigator's judgment may interfere with trial participation or evaluation;

  • 19. Known allergies or contraindications to the study drug (SXRN injection) or process-related impurities of its drug substance (e.g., spectinomycin);

  • 20. For premenopausal female participants (postmenopausal females must be amenorrheic for at least 12 months to be considered of non-childbearing potential): participants with positive serum pregnancy test, or participants of childbearing potential (including female partners of male participants) who, in the investigator's opinion, are likely to become pregnant, are breastfeeding, or are unwilling to use effective contraception during the study and for at least 6 months after the last dose of the study drug;

  • 21. Any other condition that considered by the investigator as to render the patient unsuitable for participation in the study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: 4 mg SXRN

4 mg SXRN injection is administered via intravenous infusion once daily for 5 consecutive days followed by a 2-day break, for a total of 3 weeks (21 days).

4 mg SXRN injection, intravenous infusion once daily. Dosing schedule: 5 consecutive dosing days followed by a 2-day break within a 21-day cycle. Eligible participants who complete the double-blind phase and meet predefined criteria may enter an open-label treatment phase and receive 4 mg SXRN injection following the same 21-day dosing regimen.

6 mg SXRN injection, intravenous infusion once daily. Dosing schedule: 5 consecutive dosing days followed by a 2-day break within a 21-day cycle. Eligible participants who complete the double-blind phase and meet predefined criteria may enter an open-label treatment phase and receive 4 mg SXRN injection following the same 21-day dosing regimen.

Eksperimentel: 6 mg SXRN

6 mg SXRN injection is administered via intravenous infusion once daily for 5 consecutive days followed by a 2-day break, for a total of 3 weeks (21 days).

4 mg SXRN injection, intravenous infusion once daily. Dosing schedule: 5 consecutive dosing days followed by a 2-day break within a 21-day cycle. Eligible participants who complete the double-blind phase and meet predefined criteria may enter an open-label treatment phase and receive 4 mg SXRN injection following the same 21-day dosing regimen.

6 mg SXRN injection, intravenous infusion once daily. Dosing schedule: 5 consecutive dosing days followed by a 2-day break within a 21-day cycle. Eligible participants who complete the double-blind phase and meet predefined criteria may enter an open-label treatment phase and receive 4 mg SXRN injection following the same 21-day dosing regimen.

Placebo komparator: Placebo

Placebo is administered via intravenous infusion once daily for 5 consecutive days followed by a 2-day break, for a total of 3 weeks (21 days).

Matching placebo, administered by intravenous infusion once daily. Dosing schedule: 5 consecutive dosing days followed by a 2-day break within a 21-day cycle. Eligible participants who complete the double-blind phase and meet predefined criteria may enter an open-label treatment phase and receive 4 mg SXRN injection following the same 21-day dosing regimen.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in anorexia from baseline at Week 3
Tidsramme: Baseline to Week 3

Change in anorexia from baseline assessed at Week 3 using the Functional Assessment of Anorexia/Cachexia Therapy-Anorexia/Cachexia Subscale-12 (FAACT-A/CS-12). The scale ranges from 0 to 48. Higher scores indicate better outcome.

Baseline to Week 3
Change in comprehensive physical function from baseline at Week 3
Tidsramme: Baseline to Week 3

Change in physical function from baseline assessed at Week 3 using 6-minute walk test (6MWT).

Baseline to Week 3

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in quality of life from baseline at Week 3
Tidsramme: Baseline to Week 3

Change in quality of life from baseline assessed at Week 3 using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). The score ranges from 0 to 100. Higher scores indicate better outcome.

Baseline to Week 3
Change in dietary intake from baseline at Week 3
Tidsramme: Baseline to Week 3

Change in dietary intake from baseline assessed at Week 3 using the Simplified Dietary Self-Assessment Questionnaire. The scale ranges from 1 to 5. Higher scores indicate better outcome.

Baseline to Week 3
Change in body weight/lean body mass (LBM) from baseline at Week 3
Tidsramme: Baseline to Week 3
Baseline to Week 3
Change in pain from baseline at Week 3
Tidsramme: Baseline to Week 3

Change in pain from baseline assessed at Week 3 using the analgesic medication records and the pain domain score of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). The pain domain score ranges from 0 to 100. Higher scores indicate worse outcome.

Baseline to Week 3
Change in ECOG performance status from baseline at Week 3
Tidsramme: Baseline to Week 3

Change in performance status from baseline assessed at Week 3 using the Eastern Cooperative Oncology Group (ECOG) Performance Status. Possible grades range from 0 to 5. Lower grades indicate better outcome.

Baseline to Week 3

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. december 2026

Primær færdiggørelse (Anslået)

1. august 2027

Studieafslutning (Anslået)

1. december 2027

Datoer for studieregistrering

Først indsendt

16. oktober 2026

Først indsendt, der opfyldte QC-kriterier

16. oktober 2026

Først opslået (Faktiske)

22. oktober 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. november 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • AA0103

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner